Maurice M. Russel

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.

Journal: Digestive diseases and sciences

Published: December 08, 2023

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.

Journal: Journal of Crohn's & colitis

Published: February 06, 2023

Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.

Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.

Journal: European journal of gastroenterology & hepatology

Published: January 28, 2023

Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.

Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.

Journal: Journal of Crohn's & colitis

Published: January 26, 2023

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: December 15, 2022

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: November 02, 2022

Health State Questionnaires Deployed in Ulcerative Colitis Patients: The Medical, Psychological, and Economic Perspective.

Health State Questionnaires Deployed in Ulcerative Colitis Patients: The Medical, Psychological, and Economic Perspective.

Journal: Gastro hep advances

Published: October 30, 2022

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.

Journal: European journal of gastroenterology & hepatology

Published: January 02, 2022

Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.

Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.

Journal: Inflammatory bowel diseases

Published: October 26, 2021

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.

Journal: Drug safety

Published: January 15, 2021

Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.

Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.

Journal: United European gastroenterology journal

Published: January 11, 2021

Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.

Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.

Journal: Scandinavian journal of gastroenterology

Published: December 10, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026